domingo, 18 de junio de 2017

Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment. - PubMed - NCBI

2017 Jun 9. pii: S0002-9610(17)30570-6. doi: 10.1016/j.amjsurg.2017.05.008. [Epub ahead of print]

Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment.

Kozick Z1, Hashmi A2, Dove J3, Hunsinger M4, Arora T5, Wild J6, Shabahang M7, Blansfield J8.

Author information

Abstract

BACKGROUND:

Oncotype DX (ODX) is a multi-gene tumor assay for breast cancer patients. Our objective is to assess whether eligible ODX patients received the test and whether recommendations were followed based on respective risk.

METHODS:

We retrospectively analyzed testing in patients deemed eligible for ODX using the National Cancer Data Base.

RESULTS:

A total of 158,235 patients met ODX eligibility criteria. Sixty-four percent of eligible patients did not receive the test. Non-testing rose with age. White patients were more likely to be tested (56%) versus black patients (46%, p < 0.0001). Testing was highest at academic facilities (40%). Privately insured patients were more likely to get the test compared to uninsured (45 versus 34%, p < 0.0001). Those in the highest income quartile were more likely to be tested (p < 0.001).

CONCLUSIONS:

ODX is under-utilized, with racial and socio-economic factors influencing testing. Further studies are necessary to identify ways to remove disparities and increase testing when appropriate.

SUMMARY:

This study uses the National Cancer Data Base to analyze compliance with the NCCN guidelines for Oncotype DX. Compliance with testing was thirty-six percent. Several factors influenced testing in our study, including facility type, racial and socio-economic factors.